American Society of Clinical Oncology

SHERPA: White

People

  1. Scher
    Scher
  2. Motzer
    Motzer
  3. Saltz
    Saltz
  4. Hudis
    Hudis
  5. Hensley
    Hensley
  6. Miller
    Miller
  7. Morrow
    Morrow
  8. De Angelis
    De Angelis
  9. Kelsen
    Kelsen
  10. Kris
    Kris

Groups

  1. Department of Medicine (135)
  2. Solid Tumor Oncology Division (117)
  3. Surgery (54)
  4. Epidemiology and Biostatistics (48)
  5. Survivorship Research (41)
  6. Biostatistics Service (40)
  7. Genitourinary Oncology Service (35)
  8. Hematologic Malignancies, Division of (28)
  9. GSK Faculty (27)
  10. Population Sciences Research Program (27)
Search Within
  1. "2009"
Formats
  1. Meeting Abstract (142)
  2. Journal Article (80)
Groups
  1. Department of Medicine (135)
  2. Solid Tumor Oncology Division (117)
  3. Surgery (54)
  4. Epidemiology and Biostatistics (48)
  5. Survivorship Research (41)
  6. Biostatistics Service (40)

More Groups

People
  1. Sujata Patil (16)
  2. Howard Scher (13)
  3. Robert Motzer (11)
  4. Lauren Abrey (10)
  5. Leonard Saltz (10)
  6. Clifford Hudis (9)

More People

Years
  1. 2009 (222)
Publications
  1. Journal of Clinical Oncology (219)
  2. Journal of Oncology Practice (2)
  3. ASCO News & Forum (1)

Results (222)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characteristics of young women enrolled in a high-risk breast cancer screening program
    Meeting Abstract

    Tierney, S.; Delli Carpini, J. C.; Gemignani, M. L.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Safety of a novel capecitabine dosing schedule when combined with lapatinib in patients with HER2-positive metastatic breast cancer refractory to trastuzumab
    Meeting Abstract

    Traina, T. A.; Theodoulou, M.; Feigin, K.; Patil, S.; Geneus, S.; Modi, S.; Fornier, M.; Lake, D.; Norton, L.; Hudis, C.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Prostate Cancer Clinical Trials Consortium: A multicenter mechanism for the rapid design, development, and implementation of early phase clinical trials
    Meeting Abstract

    Vinson, J.; Mathew, P.; Beer, T. M.; Carducci, M. A.; Oh, W.; Small, E.; Wilding, G.; Higano, C.; Hussain, M.; Scher, H. I.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Predicting the long-term risk of prostate cancer-specific mortality after radical prostatectomy
    Meeting Abstract

    Stephenson, A. J.; Klein, E. A.; Kattan, M. W.; Han, M.; Partin, A. W.; Walsh, P. C.; Trock, B. J.; Wood, D. P.; Eggener, S. E.; Eastham, J. A.; more...
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase II study of depsipeptide (DEP) in radioiodine (RAI)-refractory metastatic nonmedullary thyroid carcinoma
    Meeting Abstract

    Sherman, E. J.; Fury, M. G.; Tuttle, R. M.; Ghossein, R.; Stambuk, H.; Baum, M.; Lisa, D.; Su, Y. B.; Shaha, A.; Pfister, D. G.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Immunologic impact of anti-CTLA-4 therapy
    Meeting Abstract

    Sharma, P.; Tsavachidou, D.; Kamat, A.; Tang, D. N.; Chen, H.; Fu, T.; Troncoso, P.; Wolchok, J.; Logothetis, C. J.; Allison, J. P.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Hereditary diffuse gastric cancer (HDGC): Clinical characteristics of a prospective cohort of HDGC patients with and without CDH1 mutation and patients with sporadic GC
    Meeting Abstract

    Shah, M. A.; Pristyazhnyuk, Y.; Jhawer, M.; Coombes, S.; Harlan, M.; Randazzo, J.; Perera, R. J.; Pascarelli, K. M.; Coit, D.; Kelsen, D. P.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors
    Meeting Abstract

    Schwartz, G. K.; Robertson, S.; Shen, A.; Wang, E.; Pace, L.; Dials, H.; Mendelson, D.; Shannon, P.; Gordon, M.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2)
    Meeting Abstract

    Shih, J.; Yang, C.; Su, W.; Hsia, T.; Tsai, C.; Chen, Y.; Chang, H.; Terlizzi, E.; Shahidi, M.; Miller, V. A.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase II study of bevacizumab in combination with cetuximab plus irinotecan in irinotecan-refractory colorectal cancer (CRC) patients who have progressed on a bevacizumab-containing regimen (The BOND 2.5 Study)
    Meeting Abstract

    Segal, N. H.; Reidy-Lagunes, D.; Capanu, M.; Kemeny, N.; Chung, K.; Kelsen, D.; Hollywood, E.; Goodman-Davis, N.; Saltz, L. B.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save